发布求助
文献互助 智能选刊 最新文献

Clinical Lymphoma, Myeloma & Leukemia最新文献

筛选
英文 中文
OA-57 Results of a Phase 1 Clinical Trial of Belantamab Mafadotin (BelMaf) Combined With Carfilzomib, Lenalidomide, and Dexamethasone (KRd) for Multiple Myeloma (MM) After One Prior Line of Therapy (LOT) OA-57 贝兰他单抗-马法多（BelMaf）联合卡非佐米、来那度胺和地塞米松（KRd）治疗多发性骨髓瘤（MM）的 1 期临床试验结果
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01898-6
{"title":"OA-57 Results of a Phase 1 Clinical Trial of Belantamab Mafadotin (BelMaf) Combined With Carfilzomib, Lenalidomide, and Dexamethasone (KRd) for Multiple Myeloma (MM) After One Prior Line of Therapy (LOT)","authors":"","doi":"10.1016/S2152-2650(24)01898-6","DOIUrl":"10.1016/S2152-2650(24)01898-6","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-26 Single Cell Whole Genome Measurement of Genomic Heterogeneity and Clonal Evolution in Multiple Myeloma OA-26 对多发性骨髓瘤基因组异质性和克隆进化的单细胞全基因组测量
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01867-6
{"title":"OA-26 Single Cell Whole Genome Measurement of Genomic Heterogeneity and Clonal Evolution in Multiple Myeloma","authors":"","doi":"10.1016/S2152-2650(24)01867-6","DOIUrl":"10.1016/S2152-2650(24)01867-6","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-50 Phase II Study of Iberdomide Maintenance Therapy Post-Autologous Stem Cell Transplant in Multiple Myeloma: Results of a Planned Interim Analysis 多发性骨髓瘤自体干细胞移植后伊伯多米德维持疗法的 OA-50 II 期研究：计划中期分析结果
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01891-3
{"title":"OA-50 Phase II Study of Iberdomide Maintenance Therapy Post-Autologous Stem Cell Transplant in Multiple Myeloma: Results of a Planned Interim Analysis","authors":"","doi":"10.1016/S2152-2650(24)01891-3","DOIUrl":"10.1016/S2152-2650(24)01891-3","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-35 Discovery of a Novel Class MMSET Inhibitor With Specificity for t(4; 14)-Positive Multiple Myeloma OA-35 发现对 t(4; 14)阳性多发性骨髓瘤具有特异性的新型 MMSET 类抑制剂
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01876-7
{"title":"OA-35 Discovery of a Novel Class MMSET Inhibitor With Specificity for t(4; 14)-Positive Multiple Myeloma","authors":"","doi":"10.1016/S2152-2650(24)01876-7","DOIUrl":"10.1016/S2152-2650(24)01876-7","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-03 Talquetamab (tal) + Teclistamab (tec) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Updated Phase 1B Results from RedirecTT-1 With >1 Year of Follow-Up OA-03 Talquetamab (tal) + Teclistamab (tec) 用于复发性/难治性多发性骨髓瘤 (RRMM) 患者 (pts)：随访时间超过1年的RedirecTT-1最新1B期研究结果
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01844-5
{"title":"OA-03 Talquetamab (tal) + Teclistamab (tec) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Updated Phase 1B Results from RedirecTT-1 With >1 Year of Follow-Up","authors":"","doi":"10.1016/S2152-2650(24)01844-5","DOIUrl":"10.1016/S2152-2650(24)01844-5","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142309738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-48 Daratumumab (DARA)/Bortezomib/Lenalidomide/Dexamethasone (D-VRd) With D-R Maintenance (Maint) in Transplant-eligible (TE) Newly Diagnosed Myeloma (NDMM): PERSEUS Cytogenetic Risk Analysis OA-48 Daratumumab (DARA)/Bortezomib/Lenalidomide/Dexamethasone (D-VRd) with D-R Maintenance (Maint) in Transplant-eligible (TE) Newly Diagnosed Myeloma (NDMM)：PERSEUS细胞遗传学风险分析
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01889-5
{"title":"OA-48 Daratumumab (DARA)/Bortezomib/Lenalidomide/Dexamethasone (D-VRd) With D-R Maintenance (Maint) in Transplant-eligible (TE) Newly Diagnosed Myeloma (NDMM): PERSEUS Cytogenetic Risk Analysis","authors":"","doi":"10.1016/S2152-2650(24)01889-5","DOIUrl":"10.1016/S2152-2650(24)01889-5","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-09 Mezigdomide Enhances Activity of BCMA-Targeted Cellular and T-Cell Engager Therapies and Mitigates Immune Toxicity in Preclinical Models of Multiple Myeloma OA-09 麦吉多米德能增强多发性骨髓瘤临床前模型中 BCMA 靶向细胞疗法和 T 细胞诱导疗法的活性并减轻免疫毒性
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01850-0
{"title":"OA-09 Mezigdomide Enhances Activity of BCMA-Targeted Cellular and T-Cell Engager Therapies and Mitigates Immune Toxicity in Preclinical Models of Multiple Myeloma","authors":"","doi":"10.1016/S2152-2650(24)01850-0","DOIUrl":"10.1016/S2152-2650(24)01850-0","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P-028 Characteristics of Bridging Therapy and Impact of Pre-lymphodepletion Tumor Burden on Clinical Outcomes of Idecabtagene Vicleucel P-028 过渡疗法的特点以及淋巴消耗前肿瘤负担对Idecabtagene Vicleucel临床结果的影响
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01931-1
{"title":"P-028 Characteristics of Bridging Therapy and Impact of Pre-lymphodepletion Tumor Burden on Clinical Outcomes of Idecabtagene Vicleucel","authors":"","doi":"10.1016/S2152-2650(24)01931-1","DOIUrl":"10.1016/S2152-2650(24)01931-1","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P-002 Ide-Cel Real-World (RW) and Clinical Trial Long-Term Safety Experience: A Special Focus on Movement and Neurocognitive Treatment Adverse Events (MNT AEs) and Second Primary Malignancies (SPMs) P-002 Ide-Cel 真实世界 (RW) 和临床试验的长期安全性经验：特别关注运动和神经认知治疗不良事件（MNT AEs）和第二原发性恶性肿瘤（SPMs）
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01905-0
{"title":"P-002 Ide-Cel Real-World (RW) and Clinical Trial Long-Term Safety Experience: A Special Focus on Movement and Neurocognitive Treatment Adverse Events (MNT AEs) and Second Primary Malignancies (SPMs)","authors":"","doi":"10.1016/S2152-2650(24)01905-0","DOIUrl":"10.1016/S2152-2650(24)01905-0","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142312248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-33 LILRB4 Is a Promising Dual Target for Tumor Cells and Immunosuppressive Myeloid Cells in Multiple Myeloma OA-33 LILRB4 是多发性骨髓瘤中肿瘤细胞和免疫抑制性髓系细胞的理想双靶点
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01874-3
{"title":"OA-33 LILRB4 Is a Promising Dual Target for Tumor Cells and Immunosuppressive Myeloid Cells in Multiple Myeloma","authors":"","doi":"10.1016/S2152-2650(24)01874-3","DOIUrl":"10.1016/S2152-2650(24)01874-3","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信